Quantbot Technologies LP Purchases 91,111 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Quantbot Technologies LP raised its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 497.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 109,434 shares of the company's stock after purchasing an additional 91,111 shares during the period. Quantbot Technologies LP's holdings in GoodRx were worth $509,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of GDRX. Versor Investments LP purchased a new position in shares of GoodRx during the 4th quarter valued at $54,000. Verus Capital Partners LLC purchased a new stake in GoodRx during the fourth quarter valued at about $55,000. Steward Partners Investment Advisory LLC purchased a new stake in GoodRx during the fourth quarter valued at about $56,000. Aigen Investment Management LP bought a new position in GoodRx during the fourth quarter worth about $62,000. Finally, EP Wealth Advisors LLC purchased a new position in shares of GoodRx in the third quarter worth about $73,000. 63.77% of the stock is owned by institutional investors.

GoodRx Price Performance

Shares of GDRX stock traded up $0.02 during trading on Tuesday, hitting $4.43. The company had a trading volume of 1,622,521 shares, compared to its average volume of 1,365,121. The stock's 50-day moving average is $4.76 and its two-hundred day moving average is $5.23. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -147.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a 52 week low of $4.09 and a 52 week high of $9.26.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms recently commented on GDRX. Morgan Stanley cut their price objective on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Wells Fargo & Company cut their price target on GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Citigroup dropped their price objective on GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a report on Friday, January 10th. Mizuho started coverage on GoodRx in a report on Wednesday, December 4th. They set a "neutral" rating and a $5.00 target price for the company. Finally, KeyCorp lowered their price target on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $8.18.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.